Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
IDEXX Laboratories, Inc.
IDXX
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $42.4B
$555.15
▲ +3.27%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$506.91 - $769.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 0.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive veterinary diagnostic ecosystem
- Advanced proprietary testing technologies
- Strong global distribution network
- Continuous innovation in animal healthcare
Bear Case
2 risks
- Above-average volatility (beta 1.5).
- Premium valuation to Life Sciences Tools peers
Growth
Stable outlook
Increasing pet ownership and veterinary care spending
Value
Premium valuation to Life Sciences Tools peers
Momentum
Weak
-5.6% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying IDXX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 5, 2026
Reported EPS of $3.47 vs $3.41 consensus (+1.8% surprise). Revenue of $1.1B vs $1.1B expected (+2.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+1.8%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+6%
+4%
+11%
+13%
+14%
+14%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.0B
$975.5M
$954.3M
$998.4M
$1.1B
$1.1B
$1.1B
$1.1B
Margins · last 8Q
Gross
63.4%
Operating
31.8%
Profit
24.4%
Wall Street consensus
5 analysts · 60% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
60%
Hold
40%
Sell
0%
Median Price Target
$640.00
▲ +15.3% vs $555.15
Latest: UBS · $640.00 · Apr 28, 2026
1 analyst covering